SG Americas Securities LLC Makes New $73,000 Investment in Seres Therapeutics, Inc. (NASDAQ:MCRB)

SG Americas Securities LLC acquired a new position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 52,080 shares of the biotechnology company’s stock, valued at approximately $73,000.

Several other large investors also recently added to or reduced their stakes in the stock. State Street Corp increased its stake in Seres Therapeutics by 127.3% during the second quarter. State Street Corp now owns 8,564,935 shares of the biotechnology company’s stock worth $41,026,000 after acquiring an additional 4,796,626 shares during the last quarter. Federated Hermes Inc. increased its stake in Seres Therapeutics by 15.9% during the first quarter. Federated Hermes Inc. now owns 8,010,806 shares of the biotechnology company’s stock worth $57,037,000 after acquiring an additional 1,096,670 shares during the last quarter. BlackRock Inc. increased its stake in Seres Therapeutics by 19.7% during the second quarter. BlackRock Inc. now owns 7,481,227 shares of the biotechnology company’s stock worth $35,835,000 after acquiring an additional 1,232,141 shares during the last quarter. Vanguard Group Inc. increased its stake in Seres Therapeutics by 24.0% during the third quarter. Vanguard Group Inc. now owns 6,610,856 shares of the biotechnology company’s stock worth $42,442,000 after acquiring an additional 1,280,039 shares during the last quarter. Finally, Hudson Bay Capital Management LP increased its stake in Seres Therapeutics by 127.3% during the third quarter. Hudson Bay Capital Management LP now owns 1,999,800 shares of the biotechnology company’s stock worth $4,760,000 after acquiring an additional 1,119,800 shares during the last quarter. 59.34% of the stock is owned by institutional investors.

Seres Therapeutics Price Performance

Shares of NASDAQ:MCRB opened at $0.56 on Friday. Seres Therapeutics, Inc. has a 1 year low of $0.54 and a 1 year high of $6.73. The business has a 50 day simple moving average of $0.87 and a two-hundred day simple moving average of $1.13. The firm has a market capitalization of $84.55 million, a PE ratio of -0.62 and a beta of 2.23.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.50 million. Equities research analysts expect that Seres Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MCRB has been the subject of several recent analyst reports. Chardan Capital dropped their target price on Seres Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, March 6th. Oppenheimer dropped their target price on Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, March 6th.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.